Skip to main content

Meeting Materials

Poster

93
Introduction: Cognitive impairments associated with schizophrenia are burdensome and detrimental to everyday life. The Schizophrenia Cognition Rating Scale (SCoRS) is a 20-item interview-...
08/20/2024
25
Introduction: Currently, no FDA-approved pharmacological treatments satisfactorily address experiential negative symptoms (ENS) of schizophrenia. CT-155/BI 3972080 (CT-155 beta), is a pre...
08/20/2024
40
INTRODUCTION: Long-term safety, tolerability, and durability of therapeutic effect are important aspects of antipsychotic treatment.
08/20/2024
199
LY03010 (paliperidone palmitate) is in development as a pharmaceutical equivalent drug product to the listed drug (LD), INVEGA SUSTENNA® for schizophrenia and schizoaffective disorders wi...
08/20/2024
184
Introduction: Iclepertin (BI 425809), a glycine transporter-1 inhibitor, has improved cognitive impairment associated with schizophrenia (CIAS) in Phase II trials, with Phase III trials u...
08/20/2024
177
Purpose: Agitation treatment in patients with schizophrenia or bipolar disorder is challenging. Alpha-2 agonist, IGALMI™ DSF (dexmedetomidine sublingual film) reduces norepinephrine. Real...
08/20/2024
198
Introduction: Major Depressive Disorder (MDD) is characterized by depressed mood and diminished quality of life. Patient characteristics as well as patients’ experience of and response to...
08/20/2024
161
Background: This analysis used population pharmacokinetic (PopPK) modeling to characterize dosing conversions and switching strategies from intramuscular paliperidone palmitate once month...
08/20/2024
100
INTRODUCTION: Initiation of the long-acting injectable antipsychotic aripiprazole lauroxil (AL) using a one-time injection of a NanoCrystal Dispersion formulation of AL (ALNCD) and a 30 m...
08/20/2024
4
Objective: To evaluate lipid and anti-diabetic medication use pre-/post-cariprazine initiation in patients with bipolar I disorder (BP-I) or major depressive disorder (MDD).
11/26/2024
5
Introduction: Peripartum or postpartum depression (PPD) is a major depressive episode (MDE) with peripartum onset. Specific international classification of diseases (ICD) codes for PPD ar...
11/26/2024
6
Introduction: Peripartum or postpartum depression (PPD) is a major depressive episode with peripartum onset. Despite its prevalence, PPD is under-screened, underdiagnosed, and undertreate...
11/26/2024
7
Introduction A similar final common pathophysiological pathway exists between clozapine hypersensitivity, COVID infection, and certain COVID vaccines (mRNA) against heart muscle. Minimizi...
11/26/2024
8
Background: Epidemiological estimates of schizophrenia vary considerably. The aim of this study was to assess current national incidence and prevalence rates of schizophrenia in the U.S. ...
11/26/2024
9
Background: Negative symptoms in schizophrenia (NSS) and cognitive impairment associated with schizophrenia (CIAS) are linked to poor prognosis. Real-world data (RWD) from electronic heal...
11/26/2024
10
Current schizophrenia treatments often cause metabolic disturbances. KarXT, an investigational medication combining xanomeline, a muscarinic receptor agonist, and trospium chloride, a mus...
11/26/2024
11
Introduction: In the phase 3 REST-ON trial (NCT02720744), once-nightly sodium oxybate (ON-SXB) treatment in participants with narcolepsy type 1 (NT1) and 2 (NT2) resulted in statistically...
11/26/2024
12
Introduction: Research was undertaken to better understand the path to a narcolepsy diagnosis, common symptoms, and impact on work, social interactions, and mental health for people with ...
11/26/2024
13
Introduction: Immediate-release (IR) oxybate formulations require patients to awaken 2.5 to 4 hours after their first dose for a second dose. Once-nightly sodium oxybate (ON-SXB) is an ex...
11/26/2024
14
Introduction: People with narcolepsy (PWN) were surveyed to better understand desired treatment outcomes and how they relate to common symptoms, treatment awareness, and medication usage....
11/26/2024
15
Introduction: To further characterize struggles and unmet needs of people with narcolepsy (PWN), passive social listening (SL) explored how PWN describe narcolepsy using their own words. ...
11/26/2024
16
Introduction: In patients with major depressive disorder (MDD), the effects of prominent anhedonia on psychotropic medication use, healthcare resource utilization (HCRU), and health-relat...
11/26/2024
17
Hypothesis/Objective: To evaluate the effect of centanafadine (CTN), a norepinephrine, dopamine, serotonin reuptake inhibitor, on ADHD symptoms and severity from two studies in pediatric ...
11/26/2024
18
Hypothesis/Objective: Evaluate caregiver and patient perspectives of the impact of centanafadine (CTN), a norepinephrine, dopamine, serotonin reuptake inhibitor, on learning problems (LP)...
11/26/2024
19
The number of long-acting injectable (LAI) antipsychotic formulations approved for the treatment of schizophrenia (SCZ) or bipolar I disorder (BP-I) is increasing, with new dosing interva...
11/26/2024
20
Introduction: Psychiatric comorbidities are common in patients with excessive daytime sleepiness (EDS) from narcolepsy or obstructive sleep apnea (OSA). Solriamfetol (Sunosi®), a dopamine...
11/26/2024
21
Introduction: An artificial intelligence–based semantic analysis of social media posts was carried out to reveal the burden of cognitive symptoms on the daily lives of people with schizop...
11/26/2024
22
Introduction: Although the clinician perspective of schizophrenia is commonly reported and patients complete questionnaires about their disease, the spontaneous, subjective experience of ...
11/26/2024
23
Introduction: ALKS 2680 is a potent, centrally active, orally bioavailable, and highly selective orexin 2 receptor agonist being developed for the once-daily treatment of narcolepsy. Here...
11/26/2024
24
Post-traumatic stress disorder (PTSD) among civilians is a significant contributor to healthcare costs and functional impairment in the United States. While approved evidence-based treatm...
11/26/2024
26
Introduction: Post-traumatic stress disorder (PTSD) is a psychiatric disorder characterized by a variety of symptoms impairing one’s functioning. Manifestations of PTSD are complex, posin...
11/26/2024
27
Introduction: Tardive dyskinesia (TD) is a movement disorder associated with prolonged exposure to dopamine receptor blocking agents that can significantly impact one’s quality of life (Q...
11/26/2024
28
Introduction: Tardive dyskinesia (TD) is a potentially disabling involuntary movement disorder due to dopamine receptor-blocking agent exposure and can impair physical, psychological, fun...
11/26/2024
29
Background: Tardive dyskinesia (TD) significantly impacts quality of life (QoL) beyond movement symptoms. A web-based survey and chart extraction among US physicians, nurse practitioners,...
11/26/2024
30
Objective: Esketamine (Spravato®) nasal spray, an NMDA receptor antagonist, is FDA-approved for use with an oral antidepressant in adults with treatment-resistant depression. Each outpati...
11/26/2024
31
Objective: We describe 2 Phase II, multicenter, randomized, double-blind, placebo-controlled trials to provide proof of concept and dose selection for BI 1569912 for the treatment of majo...
11/26/2024
32
Anhedonia is a core feature of major depressive disorder (MDD) yet its clinical burden on patients is not well understood. This retrospective cohort study assessed depression symptoms and...
11/26/2024
33
Brexpiprazole is an atypical antipsychotic approved for use as an adjunctive therapy for treatment of Major Depressive Disorder (MDD). This retrospective cohort study assessed depressive ...
11/26/2024
34
Objective: Little real-world evidence exists comparing the benefits of long-acting injectables (LAIs) relative to daily oral antipsychotics (OAPs) in the Medicare population, which includ...
11/26/2024
35
Introduction: This study described the clinical and humanistic burden of idiopathic hypersomnia.
11/26/2024
37
Although SSRIs are the first-line treatment for major depressive disorder, providers may be hesitant to initiate a trial of SSRI if the patient presented with drug induced liver injury as...
11/26/2024
38
Aim: To assess treatment patterns in patients with attention-deficit hyperactivity disorder (ADHD) treated with serdexmethylphenidate/dexmethylphenidate (SDX/d-MPH) or comparators using r...
11/26/2024
39
BACKGROUND: The United States (US) Food and Drug Administration (FDA) approved once-every-6-months paliperidone palmitate (PP6M) on 09/01/2021. However, limited real-world evidence exists...
11/26/2024
41
Introduction: Pharmacological treatments for negative and cognitive symptoms in schizophrenia spectrum disorders (SSD) are lacking, and evidence-based psychosocial interventions are inacc...
11/26/2024
42
Background: Relapse in schizophrenia adversely affects patient outcomes, yet its influence on mortality is not well characterized.
11/26/2024
43
Background: Azetukalner is a novel, potent KV7 potassium channel opener in clinical development for epilepsy and major depressive disorder (MDD).
11/26/2024
44
Cohen’s d effect sizes, which describe standardized differences between two means (e.g., mean score changes for placebo and active drug in a clinical trial), are used to compare effects a...
11/26/2024
45
Background: Alzheimer’s disease agitation (ADA) is characterized by emotional distress, aggression, and disinhibition. AXS-05 (dextromethorphan-bupropion) is a novel, oral NMDA receptor a...
11/26/2024
46
Introduction: Research exploring patients’ experiences with idiopathic hypersomnia is limited. This qualitative study explored patients’ perspectives on the most relevant and important sy...
11/26/2024
47
Introduction: Sleep inertia, a core symptom and distinguishing feature of idiopathic hypersomnia, refers to difficulty awakening. This qualitative study generated insights into the experi...
11/26/2024
48
Tardive dyskinesia (TD) can profoundly impact patients’ daily functioning and overall quality of life, making appropriate diagnosis and management critical. This study aimed to identify c...
11/26/2024
49
Introduction: Narcolepsy type 1 (NT1) is a neurologic disorder characterized by excessive daytime sleepiness and cataplexy. Cognitive impairment, a disruptive symptom of NT1, is character...
11/26/2024
50
Objectives: Real world evidence has shown the benefits of initiating aripiprazole once-monthly 400 mg (AOM 400) early in patients living with schizophrenia; however, the impact on patient...
11/26/2024
51
Patients with major depressive disorder (MDD) can be prescribed atypical antipsychotics (AAPs) as adjunctive therapies but there is a lack of real-world evidence to understand prescribing...
11/26/2024
52
Hypothesis/Objective: To evaluate the impact of centanafadine (CTN), a norepinephrine, dopamine, serotonin reuptake inhibitor, on inattention and hyperactivity/impulsivity via caregiver-r...
11/26/2024
54
Introduction: Visuospatial attention deficits are a key characteristic of ADHD. BrianGaze is an innovative technology that leverages eye-tracking to capture changes in the angle of eye ve...
11/26/2024
55
Introduction: Several atypical antipsychotics (AAs) are approved as adjunctive treatment for major depressive disorder (MDD). Given high disability burden among MDD patients, evaluation o...
11/26/2024
56
Introduction: Non-selective N-methyl-D-aspartate (NMDA) receptor antagonists (e.g. ketamine/esketamine) have demonstrated efficacy in the treatment of MDD; however, these agents are assoc...
11/26/2024
57
Introduction: SPN-820 (oral formulation of NV-5138), is a first-in-class, rapid-acting antidepressant (RAAD) drug candidate that acts intracellularly to increase mechanistic target of ra...
11/26/2024
58
Objective: To better understand Native American patients’ experiences and perceptions of depression and treatment. Methods: Educational sessions hosted by three Tribal Health Centers brou...
11/26/2024
59
Background: Seltorexant, a selective human orexin-2 receptor antagonist, is being developed for adjunctive treatment of major depressive disorder with insomnia symptoms. This phase 1 stud...
11/26/2024
60
Objective: To compare healthcare resource utilization (HCRU) and cost among Medicaid patients with serious mental illness (SMI) based on state reimbursement rates.
11/26/2024
61
Objective: To compare psychiatry-related and all-cause healthcare resource utilization (HCRU), costs, incarceration rates, and homelessness rates among states with and without an IMD excl...
11/26/2024
62
INTRODUCTION: The combination of olanzapine and samidorphan (OLZ/SAM) provides the antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain. OLZ/SAM treatme...
11/26/2024
63
INTRODUCTION: The combination of olanzapine and samidorphan (OLZ/SAM) provides the antipsychotic efficacy of olanzapine while mitigating olanzapine-associated weight gain. OLZ/SAM treatme...
11/26/2024
64
Anhedonia is a key symptom of Major Depressive Disorder (MDD), however, there is limited knowledge about the impact of prominent anhedonia on clinical improvement and treatment satisfacti...
11/26/2024
65
KarXT, an investigational treatment for schizophrenia, combines the M1/M4 preferring muscarinic receptor agonist xanomeline with the peripherally restricted muscarinic receptor antagonist...
11/26/2024
66
Background: In data pooled from the EMERGENT-1 (NCT03697252), EMERGENT-2 (NCT04659161), and EMERGENT-3 (NCT04738123) clinical trials of adults with schizophrenia, xanomeline and trospium ...
11/26/2024
67
Introduction: The dual M1/M4 preferring muscarinic receptor agonist xanomeline in combination with the peripherally restricted pan muscarinic receptor antagonist trospium chloride is an i...
11/26/2024
68
Positive symptoms of schizophrenia (ie, psychosis) are driven by dopaminergic hyperactivity. Currently approved antipsychotics block postsynaptic D2 dopamine receptors but do not target t...
11/26/2024
69
INTRODUCTION: This post-hoc analysis examined the efficacy and safety of aripiprazole lauroxil (AL) by baseline severity of illness in the double-blind ALPINE study (NCT03345979) in patie...
11/26/2024
70
INTRODUCTION: Long-acting injectable (LAI) antipsychotic medications ensure that patients have consistent medication exposure across dosing intervals that can last 1 month or more, potent...
11/26/2024
71
Objective: Review safety and efficacy outcomes for participants with concomitant stimulant use in an open-label extension (OLE) after completing a phase 3, placebo-controlled, double-blin...
11/26/2024
72
Objective: Evaluate body weight (BW) changes with viloxazine extended release (VLX-ER) in a phase 3, double-blind, 6-week trial [NCT04016779] for adult ADHD, and its ensuing long-term, op...
11/26/2024
73
OBJECTIVE: Historically, girls and women have been thought to have milder cases of ADHD and present with predominantly inattentive ADHD symptoms. This post-hoc analysis of viloxazine ER c...
11/26/2024
74
Background: Despite increasing ADHD treatment in women, ADHD medication safety in pregnancy and lactation is not well documented. Viloxazine ER is the first ADHD medication studied under ...
11/26/2024
75
Background: A dose-response evaluation of single-dose MM120 (lysergide D-tartrate) investigated functional disability (FD), sexual dysfunction (SD), and quality of life (QoL) secondary ou...
11/26/2024
76
The patient is a 44-year-old male, diagnosed with bipolar disorder, type II and generalized anxiety disorder. He has a long history of mood swings, depression, and anxiety. Since age 18, ...
11/26/2024
77
Introduction: Based on the results of the pivotal MIRAI trial (NCT04770285), CT-152 received FDA clearance as a prescription digital therapeutic adjunct to antidepressant treatment (ADT) ...
11/26/2024
78
Introduction: CT-152 is an FDA cleared prescription digital therapeutic for treating patients with major depressive disorder (MDD) as an adjunct to antidepressant medication. The durabili...
11/26/2024
79
Introduction: CT-152 received FDA 510(k)-clearance as a prescription digital therapeutic adjunct to antidepressant treatment (ADT) in patients with major depressive disorder (MDD). CT-152...
11/26/2024
80
Objective The need for additional ADHD medication options as monotherapy or in combination with stimulants exists, as not all patients respond optimally to stimulants, which are often use...
11/26/2024
81
Background: This study assessing patient’s real-world experience through PatientsLikeMe (PLM) online platform, aims to understand the treatment experience of patients with major depressiv...
11/26/2024
82
Introduction: High sodium intake can increase blood pressure (BP) and cardiovascular risk. Individuals with narcolepsy have elevated cardiovascular comorbidity burden before considering m...
11/26/2024
83
Introduction: Psychiatric comorbidities (PC) are common in patients with idiopathic hypersomnia (IH). Low-sodium oxybate (LXB; Xywav®) is approved by the US FDA for the treatment of IH in...
11/26/2024
84
OBJECTIVE: Viloxazine extended-release (VLX-ER) is a nonstimulant FDA-approved medication for pediatric and adult ADHD treatment. Patients with ADHD often have psychiatric comorbidities, ...
11/26/2024
85
Introduction: Lumateperone is an FDA-approved antipsychotic for schizophrenia and bipolar depression. This Phase 3, randomized, double-blind, placebo-controlled, multicenter trial (NCT050...
11/26/2024
86
OBJECTIVE: To assess in Alzheimer’s disease (AD), the treatment impact of donanemab, an amyloid plaque-reducing monoclonal antibody, on readily interpretable item-measures and constructs ...
11/26/2024
87
Objective: To characterize the efficacy and safety associated with donanemab, a novel amyloid-targeting therapy (ATT).
11/26/2024
88
Bipolar I disorder (BP-I) is characterized by extremes of the mood spectrum. People diagnosed with BP-I often have comorbid mental health conditions, necessitating the use of additional p...
11/26/2024
90
The US is currently experiencing a mental health crisis, with nearly 25% of adults suffering from a mental health disorder and 29% unsure of where to seek services. This significant deman...
11/26/2024
91
According to the Health Resources and Services Administration (HRSA), more than half of the U.S. population resides in a Mental Health Professional Shortage Area (MHPSA). To address this ...
11/26/2024
92
Introduction: This analysis evaluated the effect of solriamfetol (Sunosi®), approved to treat excessive daytime sleepiness (EDS) associated with obstructive sleep apnea (OSA; 37.5–150 mg/...
11/26/2024
94
The current study examines the relationship between bicultural identity integration (BII) and bicultural students’ academic performance and mental health. A sample of 86 bicultural studen...
11/26/2024
96
TV-44749 is once-monthly, subcutaneous, extended-release injectable based on innovative copolymer delivery technology that ensures controlled release of olanzapine, designed to provide su...
11/26/2024
97
Use of intramuscular long-acting injectable (LAI) olanzapine is limited due to a boxed warning for post-injection delirium/sedation syndrome (PDSS) and associated REMS. PDSS may arise fro...
11/26/2024
98
Background: Valbenazine is a once-daily medication approved for the treatment of tardive dyskinesia (TD) and chorea associated with Huntington’s disease. Data from a 48-week, open-label s...
11/26/2024
99
Introduction: This semantic analysis of social media posts captured unsolicited, real-world experiences from people with schizophrenia to examine the impact of cognitive impairment on qua...
11/26/2024
101
Background: Postpartum depression (PPD) can impair functioning and quality of life (QoL). The Junonia study evaluated characteristics and QoL of patients with moderate or severe PPD sympt...
11/26/2024
102
Objective: To describe weight and metabolic changes associated with esketamine nasal spray (ESK) versus quetiapine extended release (QXR) treatment in patients with treatment-resistant de...
11/26/2024
103
Background: Paliperidone palmitate (PP), available as 1-month (PP1M), 3-month (PP3M) and 6-month (PP6M) formulations, has demonstrated efficacy in reducing the risk of relapse and delayin...
11/26/2024
104
Additional pharmacotherapies are needed for post-traumatic stress disorder (PTSD). This pooled post-hoc analysis evaluated key clinical efficacy data for brexpiprazole in combination with...
11/26/2024
105
A well-tolerated pharmacotherapy with consistent efficacy is needed for PTSD. This report summarizes safety data from three PTSD trials of brexpiprazole + sertraline.
11/26/2024
106
Post-traumatic stress disorder (PTSD) is a highly prevalent disorder with heterogeneous and burdensome symptoms across four symptom clusters: intrusion/re-experiencing, avoidance, negativ...
11/26/2024
107
Background: People with major depressive disorder (MDD) have an increased risk of obesity, and weight gain has been linked to antipsychotics and antidepressants (ADTs). This underscores t...
11/26/2024
108
Background: To characterize safety outcomes of adjunctive cariprazine by background antidepressant therapy (ADT), post hoc analyses were conducted on data from 2 randomized controlled tri...
11/26/2024
109
Background: Post hoc analyses of phase 3 trials for adjunctive cariprazine in major depressive disorder (MDD) characterized 4 common treatment-emergent adverse events (TEAEs).
11/26/2024
110
Background: HP-3070 (asenapine transdermal system) is indicated for adults with schizophrenia. The Food and Drug Administration recommends analyzing clinical outcome data to determine wha...
11/26/2024
111
Background: d-ATS is a transdermal dextroamphetamine formulation approved for treating ADHD in patients ≥6 years old. This study evaluates the effect of external heat on rate and extent o...
11/26/2024
112
Objective: Esketamine (ESK) nasal spray is approved in 75 countries for treatment-resistant depression (TRD) in conjunction with an oral antidepressant (OAD). Efficacy and safety of ESK m...
11/26/2024
113
Objective: Anhedonia is a key symptom and part of the diagnostic criterion of major depressive disorder (MDD). However, the relationship between anhedonia and the clinical and humanistic ...
11/26/2024
114
Background: Once-daily valbenazine is approved for tardive dyskinesia (TD) and Huntington’s disease (HD) chorea. Dysphagia is common in both disorders, and alternative modes for oral medi...
11/26/2024
115
Background Agitation associated with Dementia due to Alzheimer’s disease (AADAD), characterized by exaggerated motor activity and verbal and/or physical aggression, is common in Alzheimer...
11/26/2024
116
Introduction: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and bipolar depression. A recent randomized, double-blind, placebo-controlled trial (NCT04285515) demons...
11/26/2024
117
Introduction: Patient interviews were completed to obtain in-depth insights into excessive daytime sleepiness (EDS) experienced in idiopathic hypersomnia, obstructive sleep apnea (OSA), a...
11/26/2024
118
INTRODUCTION: Efficacy and safety of the combination of olanzapine and samidorphan (OLZ/SAM) were assessed in 6 phase 3 studies of adults with schizophrenia or bipolar I disorder. We revi...
11/26/2024
119
INTRODUCTION: Addressing negative symptoms of schizophrenia can be a treatment challenge. This post hoc analysis examined the long-term effect of the combination of olanzapine and samidor...
11/26/2024
120
Short-term safety and efficacy outcomes of centanafadine versus common attention-deficit/hyperactivity disorder (ADHD) treatments were evaluated in pediatric patients using matching-adjus...
11/26/2024
121
Objectives: To expand prior network meta-analyses investigating the relative efficacy, safety, and tolerability of xanomeline and trospium (KarXT), for the acute treatment of schizophreni...
11/26/2024
122
There is great interest in psychedelic treatments for a range of psychiatric conditions. Although many neuropsychiatric treatments have psychoactive effects, the acute effects of psychede...
11/26/2024
123
Delusions of pregnancy are fixed beliefs that one is pregnant despite evidence to the contrary. Several psychosocial factors are implicated in such delusions. This case report discusses s...
11/26/2024
124
Background: This double-blind, randomized, placebo-controlled phase 3 study (NCT04533529) compared the efficacy and safety of adjunctive seltorexant to placebo in participants with major ...
11/26/2024
125
Introduction: Narcolepsy, a rare, chronic neurological condition characterized by excessive daytime sleepiness, is associated with negative impacts to patients’ lives. Studies examining t...
11/26/2024
126
Introduction: Narcolepsy is a rare, chronic neurological disorder characterized by excessive daytime sleepiness among other symptoms, that can negatively impact patients’ lives. This stud...
11/26/2024
127
Background: The Pathway Platform was designed to enhance patient-provider engagement and encourage use of outcome measures for major depressive disorder (MDD) to improve adherence to meas...
11/26/2024
128
Background: PPD is a potentially severe mood disorder that affects 1 in 7 women within the first year after childbirth. BRII-296 is an extended-release intramuscular (IM) injectable brexa...
11/26/2024
129
Patients presenting to the Behavioral Health Emergency Room and requiring admission may have co-occurring pain, which can significantly impact their mental health. Pain management is chal...
11/26/2024
130
Background There is limited understanding of how tardive dyskinesia (TD) affects individuals with different underlying psychiatric conditions.
11/26/2024
131
Background: CT-152 received FDA clearance as a prescription digital therapeutic adjunct to antidepressant (ADT) medications for symptoms of major depressive disorder (MDD). A network meta...
11/26/2024
132
Background: The FDA recently authorized CT-152 as a prescription digital therapeutic adjunct to antidepressant (ADT) medications for patients with major depressive disorder (MDD).
11/26/2024
133
Background: Cognitive impairment is an underacknowledged aspect of schizophrenia. Individuals with schizophrenia struggle with memory, attention, and executive functioning causing conside...
11/26/2024
134
Introduction: Cognitive impairments (CI) significantly burden over half of patients with schizophrenia in the United States. Given the extensive research on treating CI, we provide a revi...
11/26/2024
135
Background: Schizophrenia is a complex condition characterized by both positive and negative symptoms. Often underrecognized are the cognitive impairments (CI). The objective of this stud...
11/26/2024
136
Neuroscience is driving a transformative shift in psychiatry, with brain neuroimaging at the forefront of personalized medicine. This poster presents preclinical and clinical approaches t...
11/26/2024
137
Introduction: Patient-digital therapeutic (DTx) bonds (digital working alliance [DWA]) may be important for DTx success. Aims: To assess whether a DWA could be established between partici...
11/26/2024
138
Background: Tardive dyskinesia (TD) is a hyperkinetic movement disorder resulting from chronic exposure to antipsychotics. TD is underdiagnosed; understanding barriers to diagnosis is an ...
11/26/2024
139
Objectives: Pimavanserin (PIM) is the only FDA approved atypical antipsychotic (AAP) for the treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP);...
11/26/2024
140
All US antipsychotic labels include boxed warnings of mortality risk in older patients with dementia-related psychosis. We compared mortality risk in patients with Parkinson’s disease psy...
11/26/2024
141
Pimavanserin is the only FDA-approved medication indicated for treatment of hallucinations and delusions associated with Parkinson’s disease psychosis (PDP). Earlier treatment of mild PDP...
11/26/2024
142
Lewy Body Dementia is an umbrella term (including dementia with Lewy Bodies [DLB] and Parkinson’s disease dementia [PDD]), for dementias associated with Lewy bodies or abnormal brain depo...
11/26/2024
143
Introduction: Navacaprant is a highly selective kappa opioid receptor antagonist with promising efficacy and safety findings in a Phase 2 major depressive disorder (MDD) study. This post-...
11/26/2024
144
Introduction: This Phase 2 study assessed efficacy and safety of navacaprant, a highly selective kappa opioid receptor antagonist, in adults with major depressive disorder (MDD).
11/26/2024
145
Major depressive disorder (MDD) is often compounded by clinically relevant insomnia symptoms (MDD-CRIS; warranting clinical attention), causing anxiety, sleep deprivation, and impaired pr...
11/26/2024
146
Major depressive disorder (MDD) patients often experience insomnia symptoms as part of their depression. This survey aimed to evaluate MDD patient needs for adjunctive treatment for insom...
11/26/2024
147
Anhedonia is a core symptom of major depressive disorder (MDD). However, there is a lack of understanding of the healthcare and humanistic burden associated with prominent anhedonia in pa...
11/26/2024
149
Hypothesis/Objective: Evaluate the efficacy and safety of once-daily extended-release centanafadine (CTN), a norepinephrine, dopamine, serotonin reuptake inhibitor, for ADHD treatment in ...
11/26/2024
150
Background: Pseudoseizures, or psychogenic non-epileptic seizures (PNES), mimic epileptic seizures but are psychological in origin, lacking abnormal electrical activity on an electroencep...
11/26/2024
151
Purpose: To examine real-world incidence of adverse events of special interest (AESIs), specifically, actively solicited events of sedation, dissociation, and increased blood pressure (BP...
11/26/2024
152
Acute agitation is common in people with schizophrenia, and the Positive and Negative Syndrome Scale – Excited Component (PANSS–EC composed of excitement, tension, hostility, uncooperativ...
11/26/2024
153
Introduction: Iclepertin (BI 425809) is a GlyT1 inhibitor in Phase III development for CIAS. Aims: To assess the safety of iclepertin in Phase I (N&#3f391 healthy volunteers [HV]; 339...
11/26/2024
154
Background: Major Depressive Disorder (MDD) is a prevalent psychiatric disorder, affecting an estimated one in five U.S. adults during their lifetime. This study aims to assess the clinic...
11/26/2024
155
Background: Negative symptoms (NS) in schizophrenia (blunted affect, alogia, avolition, asociality, and anhedonia) significantly contribute to long-term disability and diminished function...
11/26/2024
156
Background: Deutetrabenazine is approved by the United States Food and Drug Administration for treatment of tardive dyskinesia (TD) and chorea in Huntington disease (HD). This interim ana...
11/26/2024
157
Background: Real-world data on antidepressant (AD) treatment for major depressive disorder (MDD) in clinical practice are limited for all ADs including vortioxetine.
11/26/2024
158
Purpose: To investigate real-world outcomes pre- and post- pharmacogenomic (PGx) testing, this study determined 1) the proportion of patients with major depressive disorder (MDD) taking m...
11/26/2024
159
Although the relationship between stress and self-control has been studied, it is unclear if the relationship follows a linear versus an inverted U-shaped model, the latter suggesting sel...
11/26/2024
160
Background Postpartum depression (PPD) is a serious, under-studied pregnancy-related complication. Racial disparities and financial barriers can impede access to PPD treatment. Methods An...
11/26/2024
162
Background: Cognitive impairment associated with schizophrenia (CIAS) is observed in approximately 80% of schizophrenia patients and viewed as having the strongest influence on everyday f...
11/26/2024
163
Noonan syndrome (NS) is a genetic disorder with cardinal features such as unusual facies, short stature, congenital heart defects and intellectual disability or developmental delay. It is...
11/26/2024
164
Introduction: Patients with narcolepsy often exhibit neuropsychological deficits, particularly in alertness, attention, executive function, and decision-making. Solriamfetol (Sunosi®), a ...
11/26/2024
165
Introduction: Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, open-label study (NCT05875974) e...
11/26/2024
166
Introduction: Jazz DUET (Develop hypersomnia Understanding by Evaluating low-sodium oxybate Treatment) is a phase 4, prospective, multicenter, single-arm, open-label study (NCT05875974) e...
11/26/2024
167
Background: This study evaluated if central raters (CRs) in psychedelic clinical research trials experience functional unblinding to treatment allocation while assessing key endpoints due...
11/26/2024
168
Introduction: Narcolepsy type 1 (NT1) involves excessive daytime sleepiness and cataplexy episodes and is defined by low orexin levels. TAK-861, an orexin receptor 2 agonist, showed wake-...
11/26/2024
169
Introduction: Narcolepsy type 1 (NT1) involves excessive daytime sleepiness and cataplexy associated with low CSF orexin levels. TAK-861, an orexin receptor 2 agonist, showed wake-promoti...
11/26/2024
170
Introduction: ALKS 2680 is a potent, centrally active, orally bioavailable, and highly selective orexin 2 receptor agonist being developed for the once-daily treatment of narcolepsy. Safe...
11/26/2024
171
Background: Many patients with major depressive disorder (MDD) experience enduring tolerability problems associated with antidepressant treatments (ADTs), leading to discontinuation and d...
11/26/2024
172
Background: Traditional antidepressant monotherapies are associated with poor outcomes in patients with impaired symptom domains of anhedonia and interest-activity. AXS-05 (dextromethorph...
11/26/2024
173
Several treatment modalities are available for patients with PTSD, including pharmacotherapy, psychotherapy, and combination therapy. This research aims to evaluate the factors associated...
11/26/2024
174
Patient experience, including physical, mental, and emotional Quality of Life (QoL) are not well understood in post-traumatic stress disorder (PTSD) management. This study aims to underst...
11/26/2024
175
Background: While the psychological impact of posttraumatic stress disorder (PTSD) is well known, its consequences on physical health and social functioning are not well documented. We sy...
11/26/2024
176
The factors that drive willingness to seek care among civilian trauma survivors with PTSD are not well understood. Understanding these drivers is important to identify opportunities to op...
11/26/2024
178
Background: Deutetrabenazine (DTBZ) is used for the treatment of tardive dyskinesia (TD) and chorea associated with Huntington disease. DTBZ dosing starts at 12 mg/d and is titrated up by...
11/26/2024
179
Background: Deutetrabenazine demonstrated clinically significant improvements in Abnormal Involuntary Movement Scale (AIMS) scores in 12-week pivotal tardive dyskinesia (TD) trials (ARM-T...
11/26/2024
180
Individuals most in need of mental health care are often the ones who lack equitable access. Medically-underserved populations (MUPs) consist of marginalized groups who do not have adequa...
11/26/2024
181
Background TV-46000, a long-acting injectable risperidone formulation administered subcutaneously once monthly (q1m) or once every 2 months (q2m), is approved for the treatment of schizop...
11/26/2024
182
Background: TV-46000, a subcutaneous long-acting injectable risperidone formulation administered once monthly (q1m) or once every 2 months (q2m), was approved in the US in April 2023 for ...
11/26/2024
185
Introduction: Digital therapeutics (DTx) are a new treatment class for major depressive disorder (MDD). CT-152 is a novel prescription DTx recently cleared by the FDA. This randomized con...
11/26/2024
186
Background Anhedonia, a core symptom of major depressive disorder (MDD), impacts patients' quality of life and treatment outcomes. However, limited data exist on how anhedonia is dis...
11/26/2024
187
Introduction: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and bipolar depression. This Phase 3, randomized, double-blind, placebo-controlled, multicenter, interna...
11/26/2024
188
Background: This study evaluated the dose-response relationship of efficacy, safety, and tolerability for single-dose MM120 (lysergide D-tartrate) vs placebo in participants with generali...
11/26/2024
189
Risperidone, an atypical antipsychotic, is known to be the most likely of its class of medication to cause hyperprolactinemia. We present a case of a 33 year old female with no known psyc...
11/26/2024
190
Purpose: To examine whether a continuing medical education (CME) curriculum intervention can improve provider knowledge, competence, and confidence in individualizing treatment plans for ...
11/26/2024
191
Physicians are challenged to fully understand the pathophysiology of major depressive disorder (MDD) and identify the role of novel therapies. Individualizing treatment for patients with...
11/26/2024
192
This study examined whether an online CME clinical demonstration module can improve learners’ self-reported clinical behaviors related to management of MDD, identifying patients who may b...
11/26/2024
193
Background: Digital therapeutic technologies (DTx) are emerging rapidly, and clinicians are challenged to understand their benefits and how they fit into practice. Physicians require educ...
11/26/2024
194
KarXT is a novel investigational muscarinic M1/M4 receptor agonist that, unlike currently available antipsychotics, does not directly block dopamine D2 receptors. A new drug application f...
11/26/2024
195
KarXT is a novel treatment that does not directly block dopamine D2 receptors. A new drug application for KarXT was recently accepted by the FDA to treat schizophrenia in adults. As KarXT...
11/26/2024
196
KarXT is a novel treatment that does not directly block dopamine D2 receptors. A new drug application for KarXT was recently accepted by the FDA to treat schizophrenia in adults. An impor...
11/26/2024
197
Introduction: Lumateperone is an FDA-approved antipsychotic to treat schizophrenia and depressive episodes associated with bipolar I or II disorder. This prospectively defined analysis of...
11/26/2024
200
BACKGROUND: Esketamine nasal spray and transcranial magnetic stimulation (TMS) are used for treatment-resistant depression (TRD), but little is known about the sequence in which these the...
11/26/2024
201
BACKGROUND: Clinical trials for esketamine nasal spray in treatment resistant depression (TRD) often assess efficacy using Montgomery-Asberg Depression Rating Scale (MADRS)-based primary ...
11/26/2024
202
BACKGROUND: Both esketamine nasal spray and transcranial magnetic stimulation (TMS) are indicated for treatment-resistant depression (TRD), but there are no guidelines on the sequence of...
11/26/2024
203
BACKGROUND: Esketamine nasal spray and second-generation antipsychotic augmentation (SGA) are approved therapies for treatment-resistant depression (TRD). Prospective randomized ESCAPE-TR...
11/26/2024
205
Hypothesis/Objective: To evaluate the impact of centanafadine (CTN)—a norepinephrine, dopamine, serotonin reuptake inhibitor—on patient-reported assessment of the frequency of core sympto...
11/26/2024
206
Background: We report secondary/exploratory endpoints assessing patient-reported depressive symptoms, insomnia symptoms, and health-related quality of life (HRQoL) from a phase 3, double-...
11/26/2024
207
Depression treatment remains a significant clinical challenge due to the variability in patient responses to antidepressant medications. Outside of pharmacogenetic testing, established mo...
11/26/2024
#33
The SAVITRI study evaluated osavampator, a selective positive allosteric modulator of the AMPA receptor (AMPA-PAM), in adults with MDD. Compared with placebo, once-daily oral administrati...
10/17/2025
#92
This study developed and refined a conceptual model (CM) to assess psychosocial functioning in people living with schizophrenia (PLS), integrating insights from a targeted literature revi...
10/17/2025
#153
Individuals can experience moderate/severe multidimensional impact of TD even when individual AIMS component scores are mild in severity. Pronounced movements involving the muscles of fac...
10/17/2025
#168
Converging results from qualitative research (literature review, clinician interviews, and patient interviews) yielded a new conceptual disease model of PTSD that describes signs, symptom...
10/17/2025
#172
Cognitive processing therapy (CPT) can be effective in treating posttraumatic stress disorder (PTSD). Stellate ganglion block (SGB), which is an anesthetic injection that helps “reset” sy...
10/17/2025
#1
This study generated updated prevalence estimates for generalized anxiety disorder in adults in the US using real-world data, in addition to contextualizing findings through a systematic ...
10/17/2025
#3
This study assessed suicidal ideation among U.S. adults using 2022 NHWS data, with a focus on individuals with GAD and MDD. Overall, 28.4% U.S. adults reported recent suicidal thoughts, w...
10/17/2025
#17
This study surveyed psychiatrists from the US, Germany, and France on the treatment of MDD, BPD, and PTSD. Key findings include the importance of reducing suicidal ideation in MDD, varied...
10/17/2025
#20
This qualitative study explored functional impacts and outcome priorities through interviews with 15 adults with Major Depressive Disorder (MDD) and 5 clinicians. Patients reported widesp...
10/17/2025
#21
This post hoc analysis of a randomized double-blind study (NCT04599855) evaluated changes in the 5-item Montgomery-Åsberg Depression Rating Scale anhedonia factor score (a composite of it...
10/17/2025
#24
Using the PatientsLikeMe community, a 24-week real-world study was conducted in individuals with major depressive disorder (MDD) to assess goal-setting behaviors and clinical outcomes. Su...
10/17/2025
#26
Short Description: This Phase 3, double-blind, randomized study (NCT04959032) investigated the efficacy and safety of lumateperone 42 mg for relapse prevention in adult patients with schi...
10/17/2025
#41
Residual symptoms during antidepressant therapy (ADT), such as sleep disturbances and cognitive impairment, may signal incomplete ADT response and relapse risk. This study measured residu...
10/17/2025
#43
This study evaluated the cardiometabolic risks of pharmacologic treatments for MDD through a systematic review and network meta-analysis of randomized controlled trials. Results were rank...
10/17/2025
#64
A machine learning model to identify baseline factors predictive of response to aripiprazole once-monthly (AOM) in patients diagnosed with bipolar I disorder (BP-I) was developed using de...
10/17/2025
#72
Up to 50% of adults with schizophrenia switch antipsychotic medication within 2 years of treatment initiation. We conducted a real-world analysis of strategies used by healthcare provider...
10/17/2025
#79
This real-world claims analysis compared combined olanzapine/samidorphan (OLZ/SAM) versus olanzapine in patients with bipolar I disorder. OLZ/SAM was associated with significantly better ...
10/17/2025
#83
Short description: Prior pharmacokinetic studies of X/T in healthy volunteers showed dosing with food reduced trospium bioavailability, potentially impacting tolerability. This open-label...
10/17/2025
#96
TV-44749 is a once-monthly subcutaneous long-acting injectable olanzapine, designed to provide sustained efficacy without the risk of post-injection delirium/sedation syndrome (PDSS). Her...
10/17/2025
#119
CRESCENDO was a survey of the patient experience in adults with narcolepsy type 1. This subgroup analysis examined residual symptoms among respondents who reported satisfaction with curre...
10/17/2025
#124
Jazz DUET (NCT05875974) was a patient-centric, prospective, single-arm, open-label study evaluating effectiveness of low-sodium oxybate (LXB) in IH or narcolepsy. In participants with IH,...
10/17/2025
#167
Severe hypothyroidism can present with predominant psychiatric and cognitive symptoms, making diagnosis challenging when classic somatic signs are absent. This poster explores the neurops...
10/17/2025
#185
A 65-year-old male veteran with no prior psychiatric history and a past medical history of seizure disorder developed severe, treatment-resistant depression after witnessing his mother’s ...
10/17/2025
#187
This project explores the integration of mindfulness meditation with esketamine in the treatment of major depressive disorder. Conducted as a quasi-experimental pilot, the study involved ...
10/17/2025